Fabrazyme 35mg (Agalsidase Beta Vials) 35mg

Fabrazyme 35mg (Agalsidase Beta) is an enzyme replacement therapy for Fabry disease. Store between 2-8°C and protect from light. This UK-sourced vial is designed for intravenous administration under medical supervision.

Strength

35mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Sanofi

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fabrazyme 35mg is used to treat Fabry disease, a rare genetic disorder affecting enzyme function. It replaces the missing or deficient enzyme beta-galactosidase A, helping manage symptoms like pain and kidney complications. This therapy is prescribed for long-term enzyme replacement in adults and children.

Side Effects

Users may experience infusion-related reactions such as fever, chills, or nausea during administration. Some patients report improved energy levels and reduced pain over time. Individual responses vary, and effects should be monitored by a healthcare provider.

Precautions & Warnings

Fabrazyme 35mg requires refrigeration between 2-8°C and must be protected from light. It should only be handled by trained medical professionals. Patients with known allergies to agalsidase beta or its components should avoid this treatment.

Avoid Interactions

No significant drug interactions have been reported with Fabrazyme 35mg. However, patients should inform their doctor about all medications, including over-the-counter drugs and supplements. Caution is advised when combining with other therapies for Fabry disease.

Frequently Asked Questions

Fabrazyme 35mg is used to treat Fabry disease by replacing the missing enzyme beta-galactosidase A.

It is given as an intravenous infusion by a healthcare professional, typically every two weeks.

Common side effects include infusion-related reactions like fever, chills, or nausea.

No, it must be refrigerated between 2-8°C and protected from light.

Yes, it is prescribed for both adults and children with Fabry disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.